Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 2/20 | 0.31 |
| ▸ | CTSG | P08311 | 1/20 | 0.31 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | CTSD | P07339 | 1/20 | 0.30 |
| ▸ | CTSE | P14091 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4447358 | 0.67 | ELANE (0.38) | GRM2LMNAELANECTSGPRTN3 | |
| SCHEMBL4484747 | 0.64 | GRM2 (0.39) | CCR5GRM2LMNAELANECTSG | |
| SCHEMBL4455569 | 0.62 | OPRM1 (0.42) | GRM2 | |
| SCHEMBL5895589 | 0.59 | LMNA (0.46) | CCR5LMNA | |
| SCHEMBL6871261 | 0.59 | LMNA (0.46) | CCR5LMNA | |
| SCHEMBL7232754 | 0.59 | CCR5 (0.41) | CCR5LMNACTSDCTSEBACE1 | |
| SCHEMBL20780345 | 0.58 | EHMT2 (0.42) | GRM2ELANECTSGPRTN3 | |
| SCHEMBL20794186 | 0.58 | EHMT2 (0.42) | GRM2ELANECTSGPRTN3 | |
| SCHEMBL20794187 | 0.58 | EHMT2 (0.42) | GRM2ELANECTSGPRTN3 | |
| SCHEMBL22222447 | 0.58 | EHMT2 (0.42) | GRM2ELANECTSGPRTN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137577-A1 | HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137577-A1 | HETEROCYCLIC COMPOUNDS | CYP2D6, ABCG2, CYP2B6 | CCR5 1440/4885GRM2 4432/4885LMNA 2478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.